Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Pasithea Therapeutics Q3 2026 Results: Net Loss of $6.58M, Loss Widens

Pasithea Therapeutics Corp. reported a net loss of $14.7 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses to $11.1 million. The company maintained a cash position of $41.2 million as of the end of the period, down from $55.2 million at the start of the year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-6.6-3.0
Net income-6.6-3.0
EPS (diluted, $ a share)$-0.20$-0.41

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: KTTA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Pasithea Therapeutics Corp.: key numbers

Share price
$0.5000Close, Nov 16
Market cap
$18.4M
Shares outstanding
36.75MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Pasithea Therapeutics Corp.

All →
8:01 AM ET 8-K
Clinical Trial Data

Pasithea Therapeutics Clinical Trial Data

Pasithea Therapeutics announced positive initial Phase 1/1b clinical data for PAS-004 in patients with neurofibromatosis type 1 (NF1), showing that all 15 evaluable participants experienced reductions in cutaneous neurofibroma (cNF) surface area. The company also reported that the FDA has cleared its Investigational New Drug (IND) application to proceed with a Phase 2 trial of PAS-004 in adults with NF1-associated cNF.

4:06 PM ET 8-K
Other 8-K Filing

Pasithea Therapeutics Other 8-K Filing

Pasithea Therapeutics Corp. announced that its warrants (KTTAW) will expire on September 17, 2026, and will subsequently be delisted from The Nasdaq Capital Market. Any warrants not exercised prior to the expiration date will cease to be exercisable and will have no further value. The company's common stock (KTTA) will continue to trade on Nasdaq.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.